DDS (Drug Delivery System) is a technology that
delivers a drug as much as necessary for as long as necessary to the necessary location.
This technology can reduce the dose or the number of administrations, which means that it can lessen the burden on patients by enhancing the efficacy of a drug as well as ameliorating any side effects. When approved medicines are used for API in DDS formulation, we could shorten the development period, because the safety of API in human has already been confirmed.
Development period of DDS products are reduced in comparison with the standard period of time for new drug development
While PEGylation technology is popular as DDS technology for protein pharmaceuticals, our company is the only one that possesses the technology to improve the pharmacokinetics of protein by lecithinization. (The clinical trial of PC-SOD based on this technology is ongoing.) This technology can be applicable for other protein pharmaceuticals.
Unlike previous DDS carriers focusing on either of targeting or controlled-release, our stealth-type polymeric nanoparticles are the world’s first DDS carrier successfully achieving both of them. In addition to nano-PGE1 and nano-BPS (beraprost sodium) currently under development, it is possible to encapsulate other drugs into this original DDS carrier.
Encapsulating drugs in lipid emulsions allows drug pharmacokinetics to be improved. We, as the pioneer in this technology, have successfully launched lipo-PGE1 and lipo-NSAID into the market. Our partner, Beijing Tide Pharmaceutical has one of the world’s biggest manufacturing plants for lipid emulsion pharmaceuticals.